Galera
Discovering and developing novel mechanism-based therapies that have the potential to improve both treatment and outcomes for patients with cancer.
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Galera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics aimed at transforming radiotherapy in cancer treatment. The company leverages its expertise in superoxide dismutase mimetics to design drugs that reduce normal tissue toxicity from radiotherapy and enhance its anti-cancer efficacy. Galera's lead product candidate, GC4419, is a potent and highly selective small molecule dismutase mimetic currently in clinical trials for various cancer indications. The company primarily serves patients undergoing radiotherapy for cancer, focusing on those with conditions like pancreatic cancer and chronic kidney disease induced by cisplatin. Operating in the biopharmaceutical market, Galera's business model revolves around the development, clinical testing, and eventual commercialization of its proprietary drugs. Revenue generation is expected through the successful approval and sale of these therapeutics, as well as potential partnerships and licensing agreements.
Keywords: biopharmaceutical, radiotherapy, cancer treatment, superoxide dismutase mimetics, GC4419, clinical trials, pancreatic cancer, chronic kidney disease, drug development, proprietary therapeutics.